Skip to main content

Mechanical Circulatory Support: Left Ventricular Assist Devices (LVAD)

 

Left Ventricular Assist Device (LVAD)

Prisma Health is the first hospital in the midlands to perform temporary and permanent LVAD implants in patients with failing hearts and those awaiting transplants. 

The procedure involves placing a pump inside the patient to assist a failing heart. LVADs have evolved with technical sophistication that allows patients to continue to enjoy life. Prisma Health’s Advanced Heart Health Center (AHHC) offers a range of treatment options from new onset heart failure to end stage heart failure. The multidisciplinary approach of the AHHC allows the providers to tailor the care for every individual.

Prisma Health’s Advanced Heart Health Center offers a range of treatment options. There are patients on medications, as well as LVAD implant recipients who come here for treatment and oversight. 

MC Device Illustration

For heart patients who are eligible for LVAD implant, referring physicians should consider:

  • A center with an experienced LVAD team that performs implants (15 annually)
  • A multidisciplinary team that provides a comprehensive approach to patient care and knows how to mitigate any potential health threat
  • A program that offers the full breadth of education and support for ongoing LVAD care

At Prisma Health, we specialize in the HeartMate ll LVAD and the HeartWare HeartMate III. We also offer MyLVAD, a resource for patients and their loved ones.

To refer a patient, ontact us at 803-434-2762.

 

Providers

Midlands 

James O. Ampadu, MD

Cassandra Buto-Colletti, DO

Patrick J. McCann, MD

Jeffery S. Martin, MD

Rebecca S. Napier, MD

 

 *I Need Help”—A mnemonic to aid timely referral in advanced heart failure.
  Jay Baumwol, MBBS (Hons), FRACP 
  Published:February 10, 2017.DOI:https://doi.org/10.1016/j.healun.2017.02.010

Table 1 "I Need Help" - Markers of Advanced Heart Failure

I
Inotropes
Previsous or ongoing requirement for dobutaine, milrinoe, dopamine or levosimendan
N
NYHA class/Natriurectic peptides
Persisting NYHA Class III orIV and /or persistently high BNP or NY-pro-BNP
E
End-Organ Dysfunction
Worsening renal or liver dysfunction in the setting of heart failure
E
Ejection Fraction
Very low ejection fraction <20%
D
Defibrillator
Recurrent appropriate defibrillator shocks
H
Hospitalizations
More than 1 hospitalization with heart failure in the las 12 months
E
Edema/Escalating Diurectics
Persisting fluid overload and/or Increasing diurectic requirement
L
Low blood pressure
Consistently low BP with systolic
P
Prognostic medication
Inability to up-titrate (or need to descrease/cease) ACEI, B-blockers, ARNIs or MRAs

 

ACEI, angiotensin-converting enzyme inhibotor; ARNI aniotensin-receptor neprilysin inhibitor; BNP, B-type natriuretc peptide; BP blood pressure; MRA moneralocorticoid receptor antagonist; NT-ProBNP, N-terminal pro-b-type natriurectic peptide; NYHA New York Heart Association.